Stock Ratings / Health Care / PCSA / dividends

PULM (36) GELS (59) BGMS (40) CANF (31) ⌘ Pro Terminal →

Processa Pharmaceuticals Inc. (PCSA) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.89 +2.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.89

Processa Pharmaceuticals Inc. (PCSA) carries a Roarable Rating of D (Sell) with 48/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $5.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.89 (+0.20%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (48/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-4.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PCSA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (48/100 Composite)

🔍 WHY PCSA SCORES 48/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (31% of score)

FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 55.7 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: Whale & Options Positioning+11/20 pts (23% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.52+11.2% Next Q

Q2 (-2Q)

Grade D$1.69+7.1% Next Q

Q3 (-1Q)

Grade D$1.81+4.4% Next Q

Current

Grade D$1.89-5.6% Hist 90D α

Trajectory: D (40) → D (48)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PCSA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PCSA currently carries a cautious 48/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.98) forces dealer call-delta covering toward $10.76.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PCSA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PCSA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 48%NO 52%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PCSA)

✓Walkthrough of PCSA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PCSA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.00%▼ DESCENDING CHANNEL

2026-10-30O $1.81H $1.94L $1.81C $1.89VOL 25.4K

RES: $2.75SUP: $0.82SMA50: $1.85SMA200: $2.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PCSA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PCSA Butterfly Map → + Track PCSA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PCSA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PCSA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PCSA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PCSA)

Health Care Rank #398 of 1016 ⚔️ PULM vs PCSA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PCSA vs. PULM, GELS, BGMS, CANF)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Processa Pharmaceuticals Inc. (PCSA) ranks #398 by composite RQD confidence (48/100, grade D) and #941 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, PCSA leads on earnings valuation at N/A trailing P/E, while PCSA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GELS currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PCSA at 48/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PCSA ACTIVE Processa Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.16%	$5.3M	Benchmark Subject
PULM Pulmatrix Inc.	D-	36/100	—	—	-35.0%	-5.67%	$5.2M	/pulm-vs-pcsa →
GELS Gelteq Limited	C-	59/100	—	—	—	+5.11%	$5.4M	/gels-vs-pcsa →
BGMS Bio Green Med Solution Inc.	D-	40/100	—	—	-35.0%	-9.79%	$5.5M	/bgms-vs-pcsa →
CANF Can-Fite Biopharma Ltd each representing two (2)	E	31/100	—	—	-35.0%	+0.61%	$5.0M	/canf-vs-pcsa →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001533743

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Processa Pharmaceuticals Inc. (PCSA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$13.6M, operating cash flow of -$11.4M, and free cash flow of -$11.4M (-1.2% YoY). On the balance sheet, PCSA closed FY2025 with $7.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$13.6M	-$11.4M	-$11.4M	$7.8M	—
FY2024 (FY)	2024-12-31	$0	-$11.8M	-$11.2M	-$11.2M	$3.2M	—
FY2023 (FY)	2023-12-31	$0	-$11.1M	-$8.1M	-$8.1M	—	—

3. PCSA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PCSA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Processa Pharmaceuticals Inc. (NASDAQ: PCSA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 48/100 at a spot price of $1.89 (+2.16% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PCSA ranks #398 in composite RQD confidence.

How does PCSA compare to PULM and GELS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PCSA carries a Roarable D (48/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PULM (Pulmatrix Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and GELS (Gelteq Limited) posts a C- grade (59/100 RQD, P/E N/A, ROIC —, cap $5.4M). Among the 5-stock peer group, PCSA leads on earnings multiple (N/A) while PCSA leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PCSA?

Per PCSA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001533743), Processa Pharmaceuticals Inc. generated $0 in revenue, -$13.6M in net income, and -$11.4M in free cash flow against $7.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PCSA trading relative to its 50-day, 200-day, and 52-week technical levels?

PCSA last traded at $1.89 (+2.16% on volume of 104,812 shares), positioning the stock +2.16% above its 50-day simple moving average ($1.85) and -19.92% below its 200-day simple moving average ($2.36). Across its 52-week range of $1.04 to $10.25, PCSA sits at the 9.2% percentile with a 14-day RSI of 55.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.65 to $2.13).

PCSA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does PCSA pay a dividend and is it safe?

Processa Pharmaceuticals Inc. (PCSA) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: PCSA RQD Cockpit PCSA 12M Forecast PCSA Earnings & Move PCSA Dividends & DRIP PCSA Insiders & 13F PCSA Whale Options PCSA Profit Sankey PCSA News & Why